The application and prospect of CDK4/6 inhibitors in malignant solid tumors

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

(2019) Luigi Formisano et al.   Nature Communications

CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib

(2019) Tanja K. Eggersmann et al.   BIODRUGS

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial

(2019) Douglas Adkins et al.   LANCET ONCOLOGY

Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study

(2018) Norikazu Masuda et al.   CANCER SCIENCE

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

(2018) Anand Shah et al.   CLINICAL CANCER RESEARCH

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

(2018) Daniele Cretella et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

(2018) Debu Tripathy et al.   LANCET ONCOLOGY

BEYOND THE CELL CYCLE: ENHANCING THE IMMUNE SURVEILLANCE OF TUMORS VIA CDK4/6 INHIBITION

(2018) Andrea C. Chaikovsky et al.   MOLECULAR CANCER RESEARCH

Targeting the PI3K pathway in cancer: are we making headway?

(2018) Filip Janku et al.   Nature Reviews Clinical Oncology

Cyclin-dependent kinase activity is required for type I interferon production

(2018) Oya Cingöz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

(2018) Ben O’Leary et al.   Nature Communications

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

(2018) Jessica L.F. Teh et al.   Cancer Discovery

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

(2018) David A. Schaer et al.   Cell Reports

Structural insights into the functional diversity of the CDK–cyclin family

(2018) Daniel J. Wood et al.   Open Biology

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

(2018) Zhiqiang Li et al.   CANCER CELL

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor–Positive Breast Cancer

(2017) Seth A. Wander et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell-Cycle Therapeutics Come of Age

(2017) Matthew Ingham et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest

(2017) Ashleigh M. Francis et al.   MOLECULAR CANCER THERAPEUTICS

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival

(2017) Haizhen Wang et al.   NATURE

Cancer immunotherapy: Cell cycle inhibitors boost tumour immunogenicity

(2017) Kirsty Minton   NATURE REVIEWS DRUG DISCOVERY

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

(2017) S-H Chen et al.   ONCOGENE

Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer

(2017) M Pek et al.   ONCOGENE

Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer

(2017) Esther S. Kim et al.   Targeted Oncology

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma

(2017) Jin Zhou et al.   Nature Communications

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers

(2017) Smruthi Vijayaraghavan et al.   Nature Communications

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

(2017) Jeffrey Small et al.   Oncotarget

1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA

(2017) M. Taylor et al.   ANNALS OF ONCOLOGY

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

(2016) Shom Goel et al.   CANCER CELL

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

(2016) Yutaka Fujiwara et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

(2016) Andrew C. Wood et al.   CLINICAL CANCER RESEARCH

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

(2016) Julien Bollard et al.   GUT

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells

(2016) Marco De Simone et al.   IMMUNITY

Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics

(2016) Teresa Helsten et al.   MOLECULAR CANCER THERAPEUTICS

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

CDK4 and CDK6 Inhibition in Breast Cancer — A New Standard

(2016) Antonio C. Wolff   NEW ENGLAND JOURNAL OF MEDICINE

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

(2016) Jorge Franco et al.   Cell Reports

Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor

(2016) Amy S. Clark et al.   JAMA Oncology

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib

(2016) Mark A. Dickson et al.   JAMA Oncology

CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity

(2015) C. Yang et al.   CANCER RESEARCH

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2015) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

(2015) Ruben Niesvizky et al.   LEUKEMIA & LYMPHOMA

Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia

(2015) A. Nemoto et al.   MOLECULAR CANCER THERAPEUTICS

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Linking the Cell Cycle to Cell Fate Decisions

(2015) Stephen Dalton   TRENDS IN CELL BIOLOGY

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

(2012) J. P. Leonard et al.   BLOOD

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The Role of Ubiquitin in NF-κB Regulatory Pathways

(2009) Brian Skaug et al.   Annual Review of Biochemistry